The platform provides users with full 3D maps of a patient's heart. 

The new analysis provided an update on data from the PRAGUE-17 trial. 

"I want to live," the 57-year-old patient said before the procedure. "I know it's a shot in the dark, but it's my last choice.”

A new meta-analysis compared outcomes associated with the two popular DOACs. 

The solution was designed to provide high-quality ECG readings without patients needing to leave the comfort of home. 

Researchers evaluated 11 different prediction models, and each one fell short.

The study included more than 2,000 older adults who were followed for up to 12 years.